These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 17532813)

  • 1. Estimating the rate of accumulating drug resistance mutations in the HIV genome.
    Braithwaite RS; Shechter S; Chang CC; Schaefer A; Roberts MS
    Value Health; 2007; 10(3):204-13. PubMed ID: 17532813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation.
    Braithwaite RS; Shechter S; Roberts MS; Schaefer A; Bangsberg DR; Harrigan PR; Justice AC
    J Antimicrob Chemother; 2006 Nov; 58(5):1036-43. PubMed ID: 17023498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.
    Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J;
    Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [HIV resistance testing. Introduction of a new technique].
    Dragsted UB; Benfield TL
    Ugeskr Laeger; 2002 Apr; 164(17):2263-7. PubMed ID: 11989174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adherence and resistance].
    Klimkait T; Vernazza P
    Ther Umsch; 2004 Oct; 61(10):631-4. PubMed ID: 15532193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
    Kozal MJ; Hullsiek KH; Macarthur RD; Berg-Wolf Mv; Peng G; Xiang Y; Baxter JD; Uy J; Telzak EE; Novak RM;
    HIV Clin Trials; 2007; 8(6):357-70. PubMed ID: 18042501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Virological failure after 1 year of first-line ART is not associated with HIV minority drug resistance in rural Cameroon .
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Campbell NK; Taka N; Awasom C; Metzner KJ; van Lunzen J; Feldt T
    J Antimicrob Chemother; 2015 Mar; 70(3):922-5. PubMed ID: 25428920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
    Palombi L; Galluzzo CM; Andreotti M; Liotta G; Jere H; Sagno JB; Luhanga R; Mancinelli S; Amici R; Marazzi MC; Vella S; Giuliano M
    J Antimicrob Chemother; 2015 Oct; 70(10):2881-4. PubMed ID: 26111981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
    Cozzi-Lepri A; Phillips AN; Martinez-Picado J; Monforte Ad; Katlama C; Eg Hansen AB; Horban A; Bruun J; Clotet B; Lundgren JD;
    J Infect Dis; 2009 Sep; 200(5):687-97. PubMed ID: 19604043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint modeling of progression of HIV resistance mutations measured with uncertainty and failure time data.
    Hu C; De Gruttola V
    Biometrics; 2007 Mar; 63(1):60-8. PubMed ID: 17447930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV type 1 subtype diversity and drug resistance among HIV type 1-infected Kenyan patients initiating antiretroviral therapy.
    Lihana RW; Khamadi SA; Lubano K; Lwembe R; Kiptoo MK; Lagat N; Kinyua JG; Okoth FA; Songok EM; Makokha EP; Ichimura H
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1211-7. PubMed ID: 19954302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
    Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
    HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death.
    Kagay CR; Porco TC; Liechty CA; Charlebois E; Clark R; Guzman D; Moss AR; Bangsberg DR
    Clin Infect Dis; 2004 Jun; 38 Suppl 5():S414-20. PubMed ID: 15156432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.
    Chkhartishvili N; Dvali N; Gochitashvili N; Sharvadze L; Tsertsvadze T
    Georgian Med News; 2008 Dec; (165):16-22. PubMed ID: 19124911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
    Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
    Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
    BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.